A new study published in Molecular Therapy details how a chromatin remodeling pathway is activated in high-risk cancer cells and may contribute to therapeutic failure staving off effective efficacy of the CAR T cell therapy in patients with advanced colorectal cancer.
The study also suggests that the cell signaling pathway realized through Chromatin Reinforcement (CRIS) therapy may also serve as a therapeutic target in non-low-risk cancer. Our study provides new insight into the signaling pathways involved in physiological changes necessary for effective CAR T cell therapy says senior author Michael J. Guillibridge Ph. D. a UT Health San Antonio Inferior Research Professor in the Department of Biological and Physiological Sciences. CRIS therapy which was approved by the Food and Drug Administration fast track status in 2016 has stimulated immune regressions in patients with early cancer and we now show that the CRIS-stimulated signaling pathways occur in patients with advanced colorectal cancer without efficient diagnostic follow-ups.